Delix Therapeutics Retains KCSA Strategic Communications
KCSA to provide integrated public and investor relations counsel
News provided by
Share this article
Share this article
BOSTON, May 19, 2021 /PRNewswire/ Delix Therapeutics (the Company ), a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced that it has retained KCSA Strategic Communications, a leading integrated communications firm, as its agency of record (AOR).
KCSA will implement a comprehensive strategic communications program that aims to educate the investment, biopharmaceutical, and patient advocacy communities on Delix s innovative research and mission. KCSA will assist Delix in advancing the understanding of how non-hallucinogenic analogs of psychedelic compounds can be developed into safe, FDA-approved, take-at-home medicines for the treatment of central nervous system-related conditions.
Sundyne s ANSIMAG Pumps Support COVID 19 Vaccine Efforts
Share Article
ANSIMAG Pumps Specified for Use in Pharmaceutical-Grade Freeze Drier Applications Have a Lengthy Track Record of Reliability
ANSIMAG Pumps deliver the cooling mediums used to lower product temperatures in freeze drier applications.
For years, ANSIMAG pumps have played a key role in pharmaceutical-grade freeze drier applications for vaccines - and today, these applications are more important than ever in the fight against COVID-19. ARVADA, Colo. (PRWEB) March 16, 2021
Sundyne, a global leader in the design and manufacture of mission critical pumps and compressors, announced that its ANSIMAG pumps have been widely deployed in pharmaceutical-grade freeze drier applications used by several companies for vaccines, including COVID-19 vaccines.
Delaware Court of Chancery Orders Facebook to Produce Books and Records, Including Emails, but Not Attorney-Client Privileged Materials | Wilson Sonsini Goodrich & Rosati jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Article content
Facebook Inc may have paid $4.9 billion more than the maximum penalty it faced under a settlement agreement with regulators related to allegations it mishandled user privacy, according to a Wednesday court ruling.
The information made public by a Delaware judge who gleaned it from a “white paper” prepared by a law firm advising Facebook’s board of directors as they debated a proposed $5 billion settlement with the Federal Trade Commission. That agreement also protected Chief Executive Officer Mark Zuckerberg.
We apologize, but this video has failed to load.
Try refreshing your browser, or Facebook may have vastly overpaid in data privacy settlement - court filing Back to video